Congo Launches Mpox Vaccination Campaign to Address Outbreak

By Crystal Lubbe

October 23, 2024

The article from the World Health Organization (WHO) Regional Office for Africa, titled “The Democratic Republic of the Congo kicks off mpox vaccination,” provides crucial information regarding the launch of the mpox vaccination campaign in the Democratic Republic of the Congo. This initiative marks a significant effort to combat the ongoing mpox outbreak and is essential for safeguarding public health.

Launch of Vaccination Campaign

The Democratic Republic of the Congo (DRC) launched its mpox vaccination campaign on October 5, 2024, in the eastern North Kivu province. This initiative is part of the ongoing efforts to control the mpox outbreak and save lives.

Target Groups

The vaccination will prioritise several groups, including health workers, frontline responders, and other at-risk groups. The campaign will subsequently expand to 11 of the most affected health zones in Equateur, North Kivu, Sankuru, South Kivu, Sud-Ubangi, and Tshopo provinces.

Vaccine Supply

The country has received 265,000 doses of the MVA-BN vaccine, donated by the European Commission’s Health Emergency Preparedness and Response Authority, Gavi, the Vaccine Alliance, and the United States Government.

Comprehensive Response

WHO recommends that mpox vaccination be part of a comprehensive response, which includes enhanced surveillance, community engagement, contact tracing, public health and social measures, and appropriate case management. As a result, WHO and partners are working closely with national authorities to scale up and reinforce these control measures.

Expert Support

More than 300 WHO experts, previously involved in polio eradication, have now joined the mpox response. With extensive field experience, they contribute to community-based and health-facility surveillance, case investigations, contact tracing, and risk communication.

Preparation and Infrastructure

WHO has supported national health authorities in various areas, including training health workers and enhancing vaccine delivery systems and infrastructure, including vaccine storage and transportation. Furthermore, community engagement and ensuring supervision for the vaccination process are also priorities. As a result, efforts are underway to address vaccine misinformation and engage with community and religious leaders.

Mpox Situation in DRC

In 2024, the DRC has reported over 30,000 laboratory-confirmed mpox cases and 990 deaths. This accounts for 90% of the cases reported in the African region this year.

Vaccine Availability and Distribution

Mpox vaccines are currently in short supply, especially in Africa. The MVA-BN vaccine received WHO’s prequalification in September 2024, which facilitates timely access. Moreover, WHO is collaborating with partners to establish a distribution mechanism for donated doses and direct procurements from the vaccine manufacturer.

In conclusion, the vaccination campaign is a critical step in addressing the mpox outbreak in the Democratic Republic of Congo. Furthermore, this effort is supported by a comprehensive strategy that integrates multiple public health measures and emphasizes international collaboration.

Reference url

Recent Posts

Argentina WHO Withdrawal
   

Argentina WHO Withdrawal: President Milei Exits Global Health Alliance Amid COVID-19 Disputes

💡 *What happens when a country decides to withdraw from global health organizations?*
Argentina’s President Javier Milei has made the bold move to withdraw from the WHO, citing significant disagreements over health management during the pandemic. This decision raises questions about national sovereignty, cooperation, and the future of global health initiatives. Dive into the implications of Argentina’s stance and what it means for international health governance.

#SyenzaNews #globalhealth #healthcarepolicy

Gauteng HPV vaccination campaign
      

Gauteng HPV Vaccination Campaign: Protecting Girls Against Cervical Cancer

💉 Ready to protect our future generations from cervical cancer?

The Gauteng HPV vaccination campaign aims to vaccinate grade 5, 6, and 7 girls against the virus that causes most cervical cancers. By leveraging a single-dose regimen, this initiative not only enhances access to life-saving vaccines but also strives to meet ambitious global health targets.

Explore how this campaign is reshaping health outcomes in South Africa and why parental consent is key to its success.

#SyenzaNews #HealthEconomics #HealthcareInnovation #UniversalHealthCoverage

Capvaxive vaccine approval
     

Capvaxive Vaccine Approval

🌍 What if a single vaccine could significantly change the landscape of pneumococcal disease prevention in adults?

The European Medicines Agency has just recommended Merck’s Capvaxive, an innovative 21-valent pneumococcal conjugate vaccine! With robust data from multiple phase 3 trials, this potential approval marks a pivotal step in the fight against invasive Streptococcus pneumoniae infections in the EU. Look into how Capvaxive could enhance public health outcomes and offer extensive serotype coverage.

#SyenzaNews #pharmaceuticals #healthcarepolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.